📊 SGRY Key Takeaways
Is Surgery Partners, Inc. (SGRY) a Good Investment?
Surgery Partners operates with positive operating income ($65.8M, 8.1% margin) but is unprofitable at the net level (-$35.9M) due to substantial debt burden ($3.6B, 2.14x D/E). The company's inability to generate positive free cash flow (-$4.3M) despite $810.9M revenue, combined with negative returns to shareholders (ROE -2.1%, ROA -0.4%), indicates structural financial stress that outweighs modest 6.2% revenue growth.
Why Buy Surgery Partners, Inc. Stock? SGRY Key Strengths
- Positive operating income of $65.8M with 8.1% operating margin demonstrates core business capability
- Revenue growth of 6.2% YoY shows market demand for healthcare services
- Adequate short-term liquidity with current ratio of 1.86x and quick ratio of 1.69x
SGRY Stock Risks: Surgery Partners, Inc. Investment Risks
- Negative free cash flow (-$4.3M) with weak operating cash flow ($11.7M) relative to $810.9M revenue indicates poor cash generation
- High leverage (Debt/Equity 2.14x, $3.6B long-term debt) with significant interest burden crushing net profitability
- Negative net income (-$35.9M, -4.4% margin) and negative returns (ROE -2.1%, ROA -0.4%) destroying shareholder value
- Large gap between $65.8M operating income and -$35.9M net income suggests unsustainable debt servicing costs
- Capital expenditure ($16.0M) exceeds operating cash flow ($11.7M), requiring debt or external funding
Key Metrics to Watch
- Free cash flow trajectory and ability to achieve positive FCF
- Debt reduction progress and Debt/Equity ratio improvement
- Operating cash flow as percentage of revenue
- Interest expense and debt refinancing terms
- Net income path to profitability and timeline
Surgery Partners, Inc. (SGRY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Surgery Partners, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SGRY Profit Margin, ROE & Profitability Analysis
SGRY vs Healthcare Sector: How Surgery Partners, Inc. Compares
How Surgery Partners, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Surgery Partners, Inc. Stock Overvalued? SGRY Valuation Analysis 2026
Based on fundamental analysis, Surgery Partners, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Surgery Partners, Inc. Balance Sheet: SGRY Debt, Cash & Liquidity
SGRY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Surgery Partners, Inc.'s revenue has grown significantly by 49% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.09 indicates the company is currently unprofitable.
SGRY Revenue Growth, EPS Growth & YoY Performance
SGRY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $776.0M | -$35.9M | $-0.28 |
| Q3 2025 | $770.4M | -$22.7M | $-0.18 |
| Q2 2025 | $762.1M | -$2.5M | $-0.02 |
| Q1 2025 | $717.4M | -$12.4M | $-0.10 |
| Q3 2024 | $674.1M | -$4.9M | $-0.04 |
| Q2 2024 | $667.6M | -$6.0M | $-0.05 |
| Q1 2024 | $666.2M | -$12.4M | $-0.10 |
| Q3 2023 | $620.6M | -$4.9M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Surgery Partners, Inc. Dividends, Buybacks & Capital Allocation
SGRY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Surgery Partners, Inc. (CIK: 0001638833)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SGRY
What is the AI rating for SGRY?
Surgery Partners, Inc. (SGRY) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SGRY's key strengths?
Claude: Positive operating income of $65.8M with 8.1% operating margin demonstrates core business capability. Revenue growth of 6.2% YoY shows market demand for healthcare services.
What are the risks of investing in SGRY?
Claude: Negative free cash flow (-$4.3M) with weak operating cash flow ($11.7M) relative to $810.9M revenue indicates poor cash generation. High leverage (Debt/Equity 2.14x, $3.6B long-term debt) with significant interest burden crushing net profitability.
What is SGRY's revenue and growth?
Surgery Partners, Inc. reported revenue of $810.9M.
Does SGRY pay dividends?
Surgery Partners, Inc. does not currently pay dividends.
Where can I find SGRY SEC filings?
Official SEC filings for Surgery Partners, Inc. (CIK: 0001638833) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SGRY's EPS?
Surgery Partners, Inc. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SGRY a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Surgery Partners, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SGRY stock overvalued or undervalued?
Valuation metrics for SGRY: ROE of -2.1% (sector avg: 15%), net margin of -4.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SGRY stock in 2026?
Our dual AI analysis gives Surgery Partners, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SGRY's free cash flow?
Surgery Partners, Inc.'s operating cash flow is $11.7M, with capital expenditures of $16.0M. FCF margin is -0.5%.
How does SGRY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4.4% (avg: 12%), ROE -2.1% (avg: 15%), current ratio 1.86 (avg: 2).
Is Surgery Partners, Inc. carrying too much debt?
SGRY has a debt-to-equity ratio of 2.14x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.86 suggests adequate short-term liquidity.